Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook

Takeda Pharmaceutical Company (TAK) has released an update.

Takeda Pharmaceutical Company has raised its full-year management guidance for FY2024 following a robust first-half performance, driven by the successful launch of several new products and a return to double-digit growth for its established drug ENTYVIO. The company’s Growth & Launch Products segment saw an 18.7% increase at constant exchange rates, comprising nearly half of Takeda’s total revenue. With a focus on expanding its innovative pipeline, Takeda is poised for sustainable growth as it continues to invest in late-stage programs targeting high medical need areas.

For further insights into TAK stock, check out TipRanks’ Stock Analysis page.